Top-Rated StocksTop-RatedNASDAQ:RLAY Relay Therapeutics (RLAY) Stock Price, News & Analysis $5.11 -0.49 (-8.76%) (As of 11/15/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Relay Therapeutics Stock (NASDAQ:RLAY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Relay Therapeutics alerts:Sign Up Key Stats Today's Range$5.03▼$5.6350-Day Range$5.11▼$9.5152-Week Range$5.03▼$12.14Volume1.93 million shsAverage Volume1.25 million shsMarket Capitalization$854.47 millionP/E RatioN/ADividend YieldN/APrice Target$21.22Consensus RatingModerate Buy Company OverviewRelay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More… “Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Relay Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks63rd Percentile Overall ScoreRLAY MarketRank™: Relay Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 350th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingRelay Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRelay Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Relay Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Relay Therapeutics are expected to decrease in the coming year, from ($2.61) to ($2.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Relay Therapeutics is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Relay Therapeutics is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRelay Therapeutics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Relay Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.19% of the outstanding shares of Relay Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelay Therapeutics has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Relay Therapeutics has recently increased by 1.52%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRelay Therapeutics does not currently pay a dividend.Dividend GrowthRelay Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.19% of the outstanding shares of Relay Therapeutics have been sold short.Short Interest Ratio / Days to CoverRelay Therapeutics has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Relay Therapeutics has recently increased by 1.52%, indicating that investor sentiment is decreasing. News and Social Media3.3 / 5News Sentiment0.92 News SentimentRelay Therapeutics has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Relay Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for RLAY on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows5 people have added Relay Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Relay Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $51,043.00 in company stock.Percentage Held by InsidersOnly 4.32% of the stock of Relay Therapeutics is held by insiders.Percentage Held by Institutions96.98% of the stock of Relay Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Relay Therapeutics' insider trading history. Receive RLAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Relay Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RLAY Stock News HeadlinesRelay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 6,802 SharesOctober 31, 2024 | insidertrades.comFY2024 Earnings Forecast for RLAY Issued By Leerink PartnrsNovember 13, 2024 | americanbankingnews.com[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO.November 17, 2024 | Paradigm Press (Ad)Promising Pipeline and Financial Stability Drive Buy Rating for Relay TherapeuticsNovember 8, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Relay Therapeutics (RLAY)November 7, 2024 | markets.businessinsider.comBuy Rating on Relay Therapeutics: Promising Developments and Strong Financial PositionNovember 7, 2024 | markets.businessinsider.comRelay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate HighlightsNovember 6, 2024 | globenewswire.comRelay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024October 30, 2024 | globenewswire.comSee More Headlines RLAY Stock Analysis - Frequently Asked Questions How have RLAY shares performed this year? Relay Therapeutics' stock was trading at $11.01 at the beginning of the year. Since then, RLAY stock has decreased by 53.6% and is now trading at $5.1050. View the best growth stocks for 2024 here. How were Relay Therapeutics' earnings last quarter? Relay Therapeutics, Inc. (NASDAQ:RLAY) issued its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.77) by $0.14. The firm's revenue for the quarter was down 100.0% on a year-over-year basis. When did Relay Therapeutics IPO? Relay Therapeutics (RLAY) raised $250 million in an IPO on Thursday, July 16th 2020. The company issued 14,700,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO. Who are Relay Therapeutics' major shareholders? Relay Therapeutics' top institutional investors include Bellevue Group AG (5.51%), State Street Corp (3.21%), Braidwell LP (2.61%) and Geode Capital Management LLC (2.04%). Insiders that own company stock include Mark Murcko, Sanjiv Patel, Donald A Bergstrom, Peter Rahmer, Thomas Catinazzo, Brian Adams and Andy Porter. View institutional ownership trends. How do I buy shares of Relay Therapeutics? Shares of RLAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Relay Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Relay Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Novo Nordisk A/S (NVO), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings11/06/2024Today11/17/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/27/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLAY CUSIPN/A CIK1812364 Webwww.relaytx.com Phone617-370-8837FaxN/AEmployees304Year FoundedN/APrice Target and Rating Average Stock Price Target$21.22 High Stock Price Target$28.00 Low Stock Price Target$16.00 Potential Upside/Downside+315.7%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-341,970,000.00 Net MarginsN/A Pretax Margin-3,449.57% Return on Equity-45.75% Return on Assets-40.75% Debt Debt-to-Equity RatioN/A Current Ratio18.42 Quick Ratio18.42 Sales & Book Value Annual Sales$25.55 million Price / Sales26.75 Cash FlowN/A Price / Cash FlowN/A Book Value$6.27 per share Price / Book0.81Miscellaneous Outstanding Shares133,890,000Free Float128,106,000Market Cap$683.51 million OptionableOptionable Beta1.67 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:RLAY) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.